Nouhoum Diallo

Research Interests and M Phil Aims

My research areas are pathogenesis, clinical drugs development, drugs resistance, parasitology, and infectious diseases. I am particularly interested in malaria research, investigating host-parasites interactions aimed at identifying targets/strategies for novel malaria drug and vaccine development. Malaria, a disease caused by parasites of the genus Plasmodium, individuals in all continents are potentially at risk, but the burden of the disease is harboured by young children living in Sub-Saharan Africa. Malaria was responsible for ~619 000 deaths worldwide in 2022. The majority of these deaths are caused by Plasmodium falciparum.

Sequestration of P. falciparum infected erythrocytes in human brain microvasculature is the hallmark of cerebral malaria. Sequestration is mediated by the highly polymorphic surface antigen family PfEMP1 (P. falciparum erythrocyte membrane protein 1), encoded by var genes. PfEMP1 ligands expressing DC8 (IT4var19) and DC13 (HB3var03) are adhesion molecules that bind to a variety of host receptors to bring about sequestration. The identity of the key host receptors involved in cerebral malaria remains controversial, but may include endothelial protein C receptor (EPCR) and intercellular adhesion molecule 1 (ICAM-1). Other host endothelial cell receptors such as C1q Binding Protein (C1QBP) may also play a role in sequestration in the brain, but this has rarely been studied.

My M Phil aims to investigate the hypothesis that C1QBP is an important host endothelial receptor for P. falciparum infected erythrocyte adhesion in cerebral malaria. This study will provide a better understanding of the pathophysiology of cerebral malaria and identify potential ligand-receptor interactions to develop new treatments with potential to save the lives of hundreds of thousands of children.


2022 – present

  • M Phil, Evolutionary Biology, Immunology and Infection Research – Darwin Trust of Edinburgh studentship, University of Edinburgh

2015 – 2016

  • MPH, Epidemiology and diseases control – TDR scholar in implementation research at University of Ghana, School of Public Health, Legon, Accra

2000 – 2010

  • MD, General Medicine – University of Sciences, Techniques and Technologies of Bamako, Mali


Burden of malaria in mobile populations in the Greater Accra region, Ghana: a cross- sectional study.

Diallo N, Akweongo P, Maya E, Aikins M, Sarfo B. Malar J. 2017 16(1):109. doi: 10.1186/s12936-017-1751-x. PMID: 28274262

A Novel Ex Vivo Drug Assay for Assessing the Transmission-Blocking Activity of Compounds on Field-Isolated Plasmodium falciparum Gametocytes.

Ouologuem DT, Dembele L, Dara A, Kone AK, Diallo N, Sangare CPO, Ballo FI, Dao F, Goita S, Haidara AS, Traore A, Niangaly AB, Dama S, Sissoko S, Sogore F, Dara JN, Barre YN, Daou A, Cisse F, Diakite O, Doumbia D, Koumare S, Fofana B, Tandina F, Sylla D, Sacko A, Coulibaly M, Tekete MM, Ouattara A, Djimde AA. Antimicrob Agents Chemother. 2022 ;66(12):e0100122. doi: 10.1128/aac.01001-22.PMID: 36321830

Ex Vivo Plasmodium malariae Culture Method for Antimalarial Drugs Screen in the Field.

Dembele L, Diallo N, Sogore F, Diarra B, Ballo FI, Daou A, Diakite O, Bare Y, Sangare CPO, Haidara AS, Diakite SAS, Niangaly A, Diakite M, Campo B, Awandare GA, Aniweh Y, Djimde AA. ACS Infect Dis. 2021;7(11):3025-3033. doi:10.1021/acsinfecdis.1c00262. PMID: 34711047

Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali.

Dembele L, Aniweh Y, Diallo N, Sogore F, Sangare CPO, Haidara AS, Traore A, Diakité SAS, Diakite M, Campo B, Awandare GA, Djimde AA.J  Antimicrob Chemother. 2021 ;76(8):2079-2087. doi: 10.1093/jac/dkab133.PMID: 34021751

Selection of pfcrt 76t and pfmdr1 86y mutant plasmodium falciparum after treatment of uncomplicated malaria with artesunate-amodiaquine in republic of guinea.

Beavogui AH, Diawara EY, Cherif MS, Delamou A, Diallo N, Traore A, Millimouno P, Camara D, Sylla MM, Toure AA, Diallo MS, Toure S, Togo A, Camara G, Kourouma K, Sagara I, Dicko A, Djimde A. J Parasitol. 2021 ;107(5):778-782. doi: 10.1645/19-199.PMID: 34581793

Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso.

Beshir KB, Diallo N, Somé FA, Sombie S, Zongo I, Fofana B, Traore A, Dama S, Bamadio A, Traore OB, Coulibaly SA, Maurice OS, Diarra A, Kaboré JM, Kodio A, Togo AH, Dara N, Coulibaly M, Dao F, Nikiema F, Compaore YD, Kabore NT, Barry N, Soulama I, Sagara I, Sirima SB, Ouédraogo JB, Djimde A, Sutherland CJ. Antimicrob Agents Chemother. 2021 ;65(8):e0087321. doi: 10.1128/AAC.00873-21. PMID: 34060901

Different Plasmodium falciparum clearance times in two Malian villages following artesunate monotherapy.

Kone A, Sissoko S, Fofana B, Sangare CO, Dembele D, Haidara AS, Diallo N, Coulibaly A, Traore A, Toure S, Haidara K, Sanogo K, Sagara I, Beshir KB, Gil JP, Doumbo OK, Djimde AA. Int J Infect Dis. 2020 ;95:399-405. doi: 10.1016/j.ijid.2020.03.082. PMID: 32320811

Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.

West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Lancet. 2018 ;391(10128):1378-1390. doi: 10.1016/S0140-6736(18)30291-5. PMID: 29606364

Identifying Recrudescent Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity.

Beshir KB, Diallo N, Sutherland CJ.Sci Rep. 2018 Jul 4;8(1):10097. doi: 10.1038/s41598-018-28179-2.PMID: 29973679

Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali.

Maiga H, Lasry E, Diarra M, Sagara I, Bamadio A, Traore A, Coumare S, Bahonan S, Sangare B, Dicko Y, Diallo N, Tembely A, Traore D, Niangaly H, Dao F, Haidara A, Dicko A, Doumbo OK, Djimde AA. PLoS One. 2016;11(9):e0162718. doi: 10.1371/journal.pone.0162718. PMID: 27662368

Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali.

Maiga H, Lasry E, Diarra M, Sagara I, Bamadio A, Traore A, Coumare S, Bahonan S, Sangare B, Dicko Y, Diallo N, Tembely A, Traore D, Niangaly H, Dao F, Haidara A, Dicko A, Doumbo OK, Djimde AA.PLoS One. 2016 ;11(9):e0162718. doi: 10.1371/journal.pone.0162718. PMID: 27662368

Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali.

Ouattara A, Kone A, Adams M, Fofana B, Maiga AW, Hampton S, Coulibaly D, Thera MA, Diallo N, Dara A, Sagara I, Gil JP, Bjorkman A, Takala-Harrison S, Doumbo OK, Plowe CV, Djimde AA.Am J Trop Med Hyg. 2015 ;92(6):1202-6. doi: 10.4269/ajtmh.14-0605. PMID: 25918205

Toxoplasma gondii seroprevalence in Mali.

Ouologuem DT, Djimdé AA, Diallo N, Doumbo OK, Roos DS.J Parasitol. 2013 ;99(2):371-4. doi: 10.1645/GE-3239.1. PMID: 22924926

Quinine treatment selects the pfnhe-1 ms4760-1 polymorphism in Malian patients with Falciparum malaria.

Kone A, Mu J, Maiga H, Beavogui AH, Yattara O, Sagara I, Tekete MM, Traore OB, Dara A, Dama S, Diallo N, Kodio A, Traoré A, Björkman A, Gil JP, Doumbo OK, Wellems TE, Djimde AA.J Infect Dis. 2013 ;207(3):520-7. doi: 10.1093/infdis/jis691. PMID: 23162138